Key clinical point: A retrospective study of patients with relapsed/refractory non-Hodgkin lymphoma (NHL) receiving CD19-targeting chimeric antigen receptor (CAR) T-cell therapy demonstrates that fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET-CT) may be useful to predict adverse events.

Major finding: Patients with grade 0-2 cytokine release syndrome (CRS) had significantly reduced metabolic tumor volume and total lesion glycolysis versus patients with grade 3-4 CRS (P = .008 and P = .011, respectively).

Study details: A retrospective analysis of 19 patients with relapsed/refractory NHL, including 14 patients with diffuse large B-cell lymphoma.

Disclosures: The study was funded by the 973 Program, the Natural Science Foundation of China, the Key Project of Science and Technology Department of Zhejiang Province, and the Zhejiang Public Welfare Foundation. The authors reported having no conflicts of interest.